Botulinum Toxin Therapy Update:
Focus on Limb Dysfunction
Online Activity Description:
This educational program will provide a review of the mechanisms of action, therapeutic rationale, and clinical application of botulinum neurotoxin type A (BoNT-A) in the management of limb dysfunction.
Limb dystonias are sustained involuntary muscle contractions that may be persistent or intermittent and result in posturing, jerking, twisting, tremors, athetosis, or choreoathetosis.i Botulinum neurotoxins (BoNTs) injections often are the most effective treatment for the focal dystonias.
Launch Date: August 17, 2015
Expiration Date: August 17, 2017
This activity is directed to neurologists, physiatrists, pain specialists, resident physicians, nurse practitioners, registered nurses, and other allied health practitioners interested in learning more about botulinum toxin therapy.
|Laxman Bahroo, DO
Director Botulinum Toxin Clinic
Assistant Director Neurology Residency Program
Assistant Professor of Neurology
Georgetown University Hospital
|Martin Taylor, DO, PhD
Neurology / OrthoNeuro
Clinical Associate Professor, Neurology
Ohio University College of Osteopathic Medicine
|Katharine Alter, MD
Mount Washington Pediatric Hospital
|Steven Lo, MD
Department of Neurology
Georgetown University Hospital
Disclosure of Conflicts of Interest:
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Planner or Manager||Disclosure|
|Ashley Marostica, RN, MSN||– Nothing to disclose|
|Amanda Glazar, PhD||– Nothing to disclose|
|Laura Gilsdorf, MS||– Nothing to disclose|
|Dr. Alter||Has disclosed that she has received funding as a Consultant/Independent Contractor from Allergan; Honoraria from Medforce; and received royalties from Demos Medical Publishing.|
|Dr. Bahroo||Has disclosed that he has received funding as a Consultant/Independent Contractor from AbbVie and Impax Laboratories, Inc.; for Grant/Research Support from Ipsen Biopharmaceuticals, Inc. and Teva Pharmaceuticals; as a Speaker’s Bureau participant from Allergan, Ipsen Biopharmaceuticals, Inc., Lundbeck, Teva Pharmaceuticals, UCB and US WorldMeds.|
|Dr. Lo||– Nothing to disclose.|
|Dr. Taylor||Has disclosed that he has received funding as a Consultant/Independent Contractor from Allergen, Depomed Inc., and US WorldMeds; Honoraria from Allergan, Depomed Inc., and US WorldMeds; as a Speaker’s Bureau participant from Allergan, Depomed Inc., and US WorldMeds.|
Reviewers, planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity.
Applicable MedEd Consulting staff have nothing to disclose relating to the subject matter of this activity.
At the end of this activity, learners should be better able to
- Discuss the mechanism of action and the conceptual basis for therapeutic botulinum neurotoxin therapy in patients with limb dysfunction
- Evaluate commercial preparations and application of botulinum neurotoxin in limb dysfunction
- Discuss the importance of post-injection follow-up and strategies to improve patient outcomes
- Select the proper billing and coding for botulinum toxin injections
|20 minutes:||Scientific Update||– Laxman Bahroo, DO|
|25 minutes:||Limb Dystonias||– Steven Lo, MD|
|36 minutes:||Ultrasound, EMG, and Electrical Stimulation Guidance||– Katharine Alter, MD|
|20 minutes:||Billing and Coding Update||– Martin Taylor, DO, PhD|
Estimated Time to Complete Activity:
There is no fee for this education activity.
How to Earn Credit:
During the period of August 17, 2015 through August 17, 2017, participants must:
- Review the full content of the activity and the provided resource material and reflect upon its teaching.
- Complete the questions and evaluation at the end of the activity.
- Have a passing score of 70% on the post-test. You will have two (2) opportunities to complete the post-test.
Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Nursing Continuing Education
Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
This educational activity for 2.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activities.
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
This activity is provided by Global Education Group.
This activity is supported through educational grants from Allergan, Inc., Ipsen Biopharmaceuticals, Inc., Merz Pharmaceuticals, LLC and US WorldMeds, LLC.
Disclosure of Unlabeled Use and Disclaimer:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Required Computer Hardware/Software:
Please ensure the computer system you plan to use meets the following minimum requirements:
Operating System: Windows 98 or higher & Macintosh OSX 9 or higher
Internet Browser (Mac & Windows): Internet Explorer 9.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, and Opera 5 or higher
Broadband Internet connection: Cable, high-speed DSL.
Monitor Screen Resolution: 600 x 800 or higher
Media Viewing Requirements: Adobe Reader, Flash Player, and HTML5